Using tranexamic acid to reduce blood loss in abdominoplasty
The Effectiveness of Tranexamic Acid in Abdominoplasty Plastic Surgery.
This study tests if giving tranexamic acid during tummy tuck surgery can help reduce blood loss and improve recovery for patients.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Poznan University of Medical Sciences Academic / other |
| Locations | 1 site (Poznan, Poznań) |
| Trial ID | NCT06086444 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of tranexamic acid (TXA) in reducing blood loss during abdominoplasty surgery. It is a randomized placebo-controlled trial that compares the amount of blood loss in patients receiving TXA versus those receiving a placebo. The central hypothesis is that TXA administration will decrease blood loss and fibrinolysis, thereby improving surgical outcomes. The study aims to provide valuable data on the use of TXA in plastic surgery, an area where research is still developing.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 scheduled for abdominoplasty with an ASA classification of 1 or 2.
Not a fit: Patients with a BMI outside the range of 20 to 35 kg/m2, those with a history of thromboembolism, or individuals with coagulation disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and reduced blood loss for patients undergoing abdominoplasty.
How similar studies have performed: Previous studies have shown that TXA can effectively reduce blood loss in various surgical settings, suggesting potential success in this novel application within plastic surgery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled abdominoplasty * ASA 1 or 2 * age \>18 and \<75 years Exclusion Criteria: * BMI \<20 or \>35 kg/m2 * ASA 3 or \> 3 * medical history of thromboembolism * history of hematological disease * treatment with aspirin 14 days before the procedure * treatment with anticoagulants 5 days before the procedure * epilepsy * allergy to tranexamic acid * coagulation disorders
Where this trial is running
Poznan, Poznań
- Poznan University of Medical Sciences — Poznan, Poznań, Poland (Recruiting)
Study contacts
- Principal investigator: Małgorzata Domagalska, Ph.D. — Poznań University of Medical Sciences
- Study coordinator: Małgorzata Domagalska, Ph.D.
- Email: m.domagalska@icloud.com
- Phone: +48 608762068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.